{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:59Z","timestamp":1793661059628,"version":"4.5.1"},"reference-count":135,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2308085QH301"],"award-info":[{"award-number":["2308085QH301"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014980","name":"Wannan Medical College","doi-asserted-by":"publisher","award":["WK2023ZQNZ07"],"award-info":[{"award-number":["WK2023ZQNZ07"]}],"id":[{"id":"10.13039\/501100014980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014980","name":"Wannan Medical College","doi-asserted-by":"publisher","award":["WK2024XS57"],"award-info":[{"award-number":["WK2024XS57"]}],"id":[{"id":"10.13039\/501100014980","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010814","name":"Anhui Province Department of Education","doi-asserted-by":"publisher","award":["2024AH051888"],"award-info":[{"award-number":["2024AH051888"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010814","name":"Anhui Province Department of Education","doi-asserted-by":"publisher","award":["JWFX2025032"],"award-info":[{"award-number":["JWFX2025032"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010814","name":"Anhui Province Department of Education","doi-asserted-by":"publisher","award":["2023AH040249"],"award-info":[{"award-number":["2023AH040249"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010814","name":"Anhui Province Department of Education","doi-asserted-by":"publisher","award":["2022AH040171"],"award-info":[{"award-number":["2022AH040171"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117521","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:25:56Z","timestamp":1762561556000},"page":"117521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["Recent progress in developing ATR inhibitors as anticancer agents"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-3372","authenticated-orcid":false,"given":"Shaohua","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihui","family":"Nian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-9135","authenticated-orcid":false,"given":"Peng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117521_b0005","doi-asserted-by":"crossref","unstructured":"Y. Drew, F. T. Zenke, N. J. Curtin, DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications, Nat. Rev. Drug Discov. 24 (2025) 19\u201339, https:\/\/doi.org \/10.1038\/s41573-024-01060-w.","DOI":"10.1038\/s41573-024-01060-w"},{"issue":"2","key":"10.1016\/j.bcp.2025.117521_b0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell."},{"issue":"3","key":"10.1016\/j.bcp.2025.117521_b0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tibs.2010.09.005","article-title":"ATR: a master conductor of cellular responses to DNA replication stress","volume":"36","author":"Flynn","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bcp.2025.117521_b0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2025.117521_b0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/CCO.0b013e32835280c6","article-title":"Targeting the DNA damage response in oncology: past, present and future perspectives","volume":"24","author":"Basua","year":"2012","journal-title":"Curr. Opin. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"issue":"8","key":"10.1016\/j.bcp.2025.117521_b0035","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM mutations in cancer: therapeutic implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117521_b0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CMAR.S495006","article-title":"Effects of Tp53 gene mmutations on the survival of non-small cell lung cancer (NSCLC); a short review","volume":"17","author":"Zhang","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bcp.2025.117521_b0045","article-title":"An overview of the research progress of BRCA gene mutations in breast cancer","volume":"1878","author":"Wan","year":"2023","journal-title":"BBA Rev. cancer"},{"key":"10.1016\/j.bcp.2025.117521_b0050","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: tumor suppressor and metabolic regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117521_b0055","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117521_b0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s00210-024-03444-6","article-title":"Potential promising of synthetic lethality in cancer research and treatment","volume":"398","author":"Fath","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.bcp.2025.117521_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116288","article-title":"The power and the promise of synthetic lethality for clinical application in cancer treatment","volume":"172","author":"Liu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"23","key":"10.1016\/j.bcp.2025.117521_b0070","doi-asserted-by":"crossref","first-page":"14151","DOI":"10.1021\/acs.jmedchem.0c00766","article-title":"Synthetic Lethality through the Lens of Medicinal Chemistry","volume":"63","author":"Myers","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116804","article-title":"An update on small molecule compounds targeting synthetic lethality for cancer therapy","volume":"278","author":"Luo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0080","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.bcp.2025.117521_b0085","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0090","doi-asserted-by":"crossref","unstructured":"M. G. Nizi, M. M. Maksimainen, L. Lehti\u00f6, O. Tabarrini, Medicinal chemistry perspective on targeting new horizons of synthetic lethal, J. Med. Chem. 65 (11) (2022) 7532\u20137560, https:\/\/doi.org\/10. 1021\/acs.jmedchem.2c00281.","DOI":"10.1021\/acs.jmedchem.2c00281"},{"issue":"24","key":"10.1016\/j.bcp.2025.117521_b0095","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Bio."},{"key":"10.1016\/j.bcp.2025.117521_b0105","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0968-0004(00)01563-2","article-title":"FAT: a novel domain in PIK-related kinases","volume":"25","author":"Bosotti","year":"2000","journal-title":"Trends in Biochemical Sciences"},{"key":"10.1016\/j.bcp.2025.117521_b0115","doi-asserted-by":"crossref","unstructured":"D. A. Mordes, G. G. Glick, R. Zhao, D. Cortez, TopBP1 activates ATR through ATRIP and a PIKK regulatory domain, Gene Dev 22 (2008) 1478\u20131489, http:\/\/www.genesdev.org\/cgi\/doi\/10.1101\/ga d.1666208.","DOI":"10.1101\/gad.1666208"},{"issue":"13","key":"10.1016\/j.bcp.2025.117521_b0120","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.scib.2025.05.009","article-title":"Molecular architecture and inhibition mechanism of human ATR-ATRIP","volume":"70","author":"Wang","year":"2025","journal-title":"Science Bulletin"},{"key":"10.1016\/j.bcp.2025.117521_b0125","doi-asserted-by":"crossref","unstructured":"Q. Rao, M. Liu, Y. Tian, Z. Wu, Y. Hao, L. Song, Z. Qin, C. Ding, H. W. Wang, J. Wang, Y. Xu, Cryo-EM structure of human ATR-ATRIP complex, Cell Research 28 (2018) 143\u2013156, https:\/\/doi.org\/1 0.1038\/cr.2017.158.","DOI":"10.1038\/cr.2017.158"},{"issue":"18","key":"10.1016\/j.bcp.2025.117521_b0130","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1128\/MCB.00326-08","article-title":"A novel Tel1\/ATM N-terminal motif, TAN, is essential for telomere length maintenance and a DNA damage response","volume":"28","author":"Seidel","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117521_b0135","doi-asserted-by":"crossref","unstructured":"F. M. Barnieh, P. M. Loadman, R. A. Falconer, Progress towards a clinically-successful ATR inhibitor for cancer therapy, Curr. Res. Pharmacol. Drug Discov. 2 (2021) 100017, https:\/\/doi.org\/10.10 16\/j.crphar.2021.100017.","DOI":"10.1016\/j.crphar.2021.100017"},{"issue":"8","key":"10.1016\/j.bcp.2025.117521_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103662","article-title":"Targeting ATM and ATR for cancer therapeutics: inhibitors in clinic","volume":"28","author":"Priya","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2025.117521_b0145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.bcp.2025.117521_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114187","article-title":"Discovery of a potent and highly selective inhibitor of Ataxia telangiectasia mutated and rad3-related (ATR) kinase: structural activity relationship and antitumor activity both in vitro and in vivo","volume":"232","author":"Bin","year":"2022","journal-title":"Eur. J. Med. Chem"},{"key":"10.1016\/j.bcp.2025.117521_b0155","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bcp.2025.117521_b0160","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","article-title":"Targeting ATR in patients with cancer","volume":"21","author":"Ngoi","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0165","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.currproblcancer.2017.05.002","article-title":"Targeting ATR in cancer medicine","volume":"41","author":"Sundar","year":"2017","journal-title":"Curr. Probl. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2025.117521_b0170","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2025.117521_b0175","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","article-title":"Targeting ATR in cancer","volume":"18","author":"Lecona","year":"2018","journal-title":"Nat. Rev. Cancer."},{"issue":"2","key":"10.1016\/j.bcp.2025.117521_b0180","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"S, Grant, New insights into checkpoint kinase 1 (Chk1) in the DNA damage response (DDR) signaling network: rationale for employing Chk1 inhibitors in cancer therapeutics","volume":"16","author":"Dai","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117521_b0185","doi-asserted-by":"crossref","unstructured":"M.T.Dillon,K.J.Harrington, Targeting ATR for cancer therapy: ATR-targeted drug candidates, Cancer Drug Discovery and Development, Humana Press, Cham. (2018) 99-127.","DOI":"10.1007\/978-3-319-75836-7_5"},{"issue":"21","key":"10.1016\/j.bcp.2025.117521_b0190","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117521_b0195","doi-asserted-by":"crossref","unstructured":"T. Chena, F. K. Middletona, S. Falconb, P. M. Reaperb, J. R. Pollardb, N. J. Curtina, Development of pharmacodynamic biomarkers for ATR inhibitors, Mol. Oncol. 9 (2) (2015) 463\u2013472, https:\/\/doi.org\/ 10.1016\/j.molonc.2014.09.012.","DOI":"10.1016\/j.molonc.2014.09.012"},{"key":"10.1016\/j.bcp.2025.117521_b0200","doi-asserted-by":"crossref","unstructured":"J. C. Saldivara, D. Cortezb, K. A. Cimpricha, The essential kinase ATR: ensuring faithful duplication of a challenging genome, Nat. Rev. Mol. Cell Biol. 18 (10) (2017) 622\u2013636, https:\/\/doi.org \/10.1038\/nrm.2017.67.","DOI":"10.1038\/nrm.2017.67"},{"key":"10.1016\/j.bcp.2025.117521_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116781","article-title":"Progress of ATM inhibitors: Opportunities and challenges","volume":"277","author":"Du","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101038","article-title":"Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy","volume":"57","author":"Schneider","year":"2024","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.bcp.2025.117521_b0215","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers16061139","article-title":"Triple-negative breast cancer and emerging therapeutic strategies: ATR and CHK1\/2 as promising targets","volume":"16","author":"Soffanidi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2025.117521_b0220","doi-asserted-by":"crossref","unstructured":"D. Mavroeidi, A. Georganta, E. Panagiotou, K. Syrigos, V. L. Souliotis, Targeting ATR pathway in solid tumors: evidence of improving therapeutic outcomes, Int. J. Mol. Sci. 25 (5) (2024) 2767, https:\/\/ doi.org\/10.3390\/ijms25052767.","DOI":"10.3390\/ijms25052767"},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0225","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","article-title":"Emerging strategies for cancer therapy by ATR inhibitors","volume":"114","author":"Yano","year":"2023","journal-title":"Cancer Sci."},{"issue":"17","key":"10.1016\/j.bcp.2025.117521_b0230","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0235","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by Schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"21","key":"10.1016\/j.bcp.2025.117521_b0240","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1073\/pnas.1120508109","article-title":"Revival of the abandoned therapeutic Wortmannin by nanoparticle drug delivery","volume":"109","author":"Karvea","year":"2012","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.bcp.2025.117521_b0245","first-page":"94","article-title":"Pterostilbene suppresses inflammation-induced melanoma metastasis by impeding neutrophil elastase-mediated thrombospondin-1 degradation","volume":"15","author":"Su","year":"2023","journal-title":"Chin. Herb. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0250","first-page":"528","article-title":"Molecular mechanisms of anti-cancer bioactivities of seaweed polysaccharides","volume":"14","author":"Liu","year":"2022","journal-title":"Chin. Herb. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117521_b0255","first-page":"327","article-title":"Ethnopharmacology, phytochemistry, pharmacology and product application of platycodon grandiflorum: A review","volume":"16","author":"Zhang","year":"2024","journal-title":"Chin. Herb. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0260","first-page":"479","article-title":"Analysis on internal mechanism of zedoary turmeric in treatment of liver cancer based on pharmacodynamic substances and pharmacodynamic groups","volume":"14","author":"Li","year":"2022","journal-title":"Chin. Herb. Med."},{"issue":"2","key":"10.1016\/j.bcp.2025.117521_b0265","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1254\/jphs.13048FP","article-title":"Differential effect of Schisandrin B stereoisomers on ATR-mediated DNA damage checkpoint signaling","volume":"122","author":"Tatewaki","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2025.117521_b0270","doi-asserted-by":"crossref","unstructured":"M. Sun, X. Xu, Q. Lu, Q. Pan, X. Hu, Schisandrin B: a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein, Cancer Lett. 246 (1-2) (2007) 300\u2013307, https:\/\/doi.org\/1 0.1016\/j.canlet.2006.03.009.","DOI":"10.1016\/j.canlet.2006.03.009"},{"key":"10.1016\/j.bcp.2025.117521_b0275","doi-asserted-by":"crossref","unstructured":"A. Peasland, L.Z. Wang, E. Rowling, S. Kyle, T. Chen, A. Hopkins, W.A. Cliby, J. Sarkaria, G. Beale, R.J. Edmondson, N.J. Curtin, Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines, Br. J. Cancer 105(15) (2011) 372\u2013381, https:\/\/ doi.org\/10.1038\/bjc.2011.243.","DOI":"10.1038\/bjc.2011.243"},{"key":"10.1016\/j.bcp.2025.117521_b0280","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1021\/jm990628o","article-title":"Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles","volume":"43","author":"Arris","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0285","doi-asserted-by":"crossref","unstructured":"V. Mesguiche, R. J. Parsons, C. E. Arris, J. Bentley, F. T. Boyle, N. J. Curtin, T. G. Davies, J. A. Endicott, A. E. Gibson, B. T. Golding, R. J. Griffin, P. Jewsbury, L. N. Johnson, D. R. Newell, M. E. M. Noble, L. Z. Wang, I. R. Hardcastlea, 4-alkoxy-2,6-diaminopyrimidine tetrahydro-pyrazolo derivatives: inhibitors of cyclin dependent kinases 1 and 2, Bioorg. Med. Chem. Lett. 13 (2) (2003) 217\u2013222, https: \/\/doi.org\/ 10.1016\/S0960-894X(02)00884-3.","DOI":"10.1016\/S0960-894X(02)00884-3"},{"key":"10.1016\/j.bcp.2025.117521_b0290","doi-asserted-by":"crossref","unstructured":"L. I. Toledo, M. Murga, R. Zur, R. Soria, A. Rodriguez, S. Martinez, J. Oyarzabal, J. Pastor, J. R. Bischoff, O. F. Capetillo, A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations, Nat. Struct. Mol. Biol.18 (6) (2011) 721\u2013727, https:\/\/doi.org\/10.1038 \/nsmb.2076.","DOI":"10.1038\/nsmb.2076"},{"key":"10.1016\/j.bcp.2025.117521_b0295","doi-asserted-by":"crossref","unstructured":"S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Che\u2018ne, A. D. Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. Garc\u0131\u0301a-Echeverr\u0131\u0301a, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity, Mol. Cancer Ther. 7 (7) (2008) 1851\u20131863, https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0017.","DOI":"10.1158\/1535-7163.MCT-08-0017"},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0300","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3892\/mmr.2021.11940","article-title":"Dual PI3K\/mTOR inhibitor NVPBEZ235 decreases the proliferation of doxorubicin-resistant K562 cells","volume":"23","author":"Li","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0305","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/jm101520v","article-title":"Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)-phenyl)benzo[h][1,6]naphthyridin-2 (1H) -one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer","volume":"54","author":"Liu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2025.117521_b0310","first-page":"2574","article-title":"Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR","volume":"73","author":"Liu","year":"2013","journal-title":"ATM, and ATR, Cancer Res."},{"key":"10.1016\/j.bcp.2025.117521_b0315","doi-asserted-by":"crossref","unstructured":"R. Bhakuni, A. Shaikb, B. Priyaa, S. Kirubakaranb, Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor, Bioorg. Med. Chem. Lett. 30 (23) (2020) 127517, https:\/\/doi. org\/10.1016\/j.bmcl.2020.127517.","DOI":"10.1016\/j.bmcl.2020.127517"},{"key":"10.1016\/j.bcp.2025.117521_b0320","doi-asserted-by":"crossref","unstructured":"A. Shaik, R. Bhakuni, S. Kirubakaran, Design, synthesis, and docking studies of new Torin2 analogs as potential ATR\/mTOR kinase inhibitors, Molecules 23(5) (2018) 992, https:\/\/doi.org\/10.339 0\/molecules23050992.","DOI":"10.3390\/molecules23050992"},{"issue":"1","key":"10.1016\/j.bcp.2025.117521_b0325","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/ml500353p","article-title":"Structure-based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors","volume":"6","author":"Barsanti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117521_b0330","doi-asserted-by":"crossref","unstructured":"P. A Barsanti, Y. Pan, Y. Lu, R. Jain, M. Cox, R. J. Aversa, M. P. Dillon, R. Elling, C. Hu, X. Jin, M. Knapp, J. Lan, S. Ramurthy, P. Rudewicz, L. Setti, S. Subramanian, M. Mathur, L. Taricani, G. Thomas, L. Xiao, Q. Yue, Structure-based drug design of novel, potent, and selective Azabenzimidazoles (ABI) as ATR Inhibitors, ACS Med. Chem. Lett. 6 (1) (2015) 42\u201346, https:\/\/ doi.org\/10.1021\/ml500352s.","DOI":"10.1021\/ml500352s"},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0335","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of Ataxia telangiectasia mutated and rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101743","article-title":"The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin","volume":"36","author":"Su","year":"2023","journal-title":"Trans. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117521_b0345","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3390\/ijms24032315","article-title":"The ATR inhibitor VE-821 enhances the radiosensitivity and suppresses DNA repair mechanisms of human chondrosarcoma cells","volume":"24","author":"Lohberger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bcp.2025.117521_b0350","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2025.117521_b0355","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2025.117521_b0360","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"Br. J. Cancer."},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0365","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2025.117521_b0370","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.jmb.2017.04.006","article-title":"Rationally designed PI3K\u03b1 mutants to mimic ATR and their use to understand binding specificity of ATR inhibitors","volume":"429","author":"Lu","year":"2017","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2025.117521_b0375","doi-asserted-by":"crossref","unstructured":"U. L\u00fccking, L. Wortmann, A. M. Wengner, J. Lefranc, P. Lienau, H. Briem, G. Siemeister, U. B\u00f6mer, K. Denner, M. Schafer, M. Koppitz, K. Eis, F. Bartels, B. Bader, W. Bone, D. Moosmayer, S. J. Holton, U. Eberspac\u0308her, J. Grudzinska-Goebel, C. Schatz, G. Deeg, D. Mumberg, F. von Nussbaum, Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models, J. Med. Chem. 63 (13) (2020) 7293\u20137325, https:\/\/doi.org\/1 0.1021\/acs.jmedchem.0c00369.","DOI":"10.1021\/acs.jmedchem.0c00369"},{"key":"10.1016\/j.bcp.2025.117521_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115370","article-title":"Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of Ataxia telangiectasia mutated and rad3 related (ATR) kinase","volume":"255","author":"Duan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106535","article-title":"Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors","volume":"136","author":"Duan","year":"2023","journal-title":"Bioorganic Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128651","article-title":"Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors","volume":"63","author":"Chen","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2025.117521_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114945","article-title":"Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design","volume":"246","author":"Qi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2025.117521_b0400","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant ATR inhibitor for the treatment of advanced malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0405","unstructured":"X. Li, H. Dong, D. Bai, F. He, W. Tao, Pyrazole and heteraryl derivatives, their preparation methods and applications in medicine, 2021. WO2021098811A1, May 27."},{"key":"10.1016\/j.bcp.2025.117521_b0410","unstructured":"Z. Zhao, W. Yang, Z. Wu, C. Tong, D. Gao, Heterocyclic condensed pyrimidine derivatives, pharmaceutical compositions thereof, and applications, 2023. CN111205310B, Dec 19."},{"key":"10.1016\/j.bcp.2025.117521_b0415","unstructured":"D. F. M. Emilia, J. Philip, C. C. Lawrence, C. J. Bryant, R. S. K. Vijayan, J. M. Garrett, L. Sarah, L. David, Heterocyclic inhibitors of ATR kinase, 2019. WO2019014618A1, Feb 17."},{"key":"10.1016\/j.bcp.2025.117521_b0420","unstructured":"Y. P. Zhao, H. J. Wang, B. Liu, Y. Y. Jiang, W. T. Zhong, H. F. Xu, H. L. Zhang, C. C. Huang, N. Tian, J. Zhao, J. Li, W. N. Liu, L.Y. Zhou, Y. Liu, 2,4,6-trisubstituted pyrimidines as ATR kinase inhibitors, 2020. CN112047938A, Dec 8."},{"key":"10.1016\/j.bcp.2025.117521_b0425","doi-asserted-by":"crossref","unstructured":"R. Knegtel, J. D. Charrier, S. Durrant, C. Davis, Mi. O\u2019Donnell, P. Storck, S. MacCormick, D. Kay, J. Pinder, A. Virani, H. Twin, M. Griffiths, P. Reaper, P. Littlewood, S. Young, J. Golec, J. PollardRational, Design of 5 (4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl) isoxazole-5-yl) pyrazin-2-amine (VX970, M6620): optimization of intra- and inter-molecular polar interactions of a new Ataxia telangiectasia mutated and rad3-related (ATR) kinase inhibitor, J. Med. Chem. 62 (11) (2019) 5547\u22125561, https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00426.","DOI":"10.1021\/acs.jmedchem.9b00426"},{"key":"10.1016\/j.bcp.2025.117521_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","volume":"210","author":"Gorecki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117521_b0435","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Discov."},{"issue":"14","key":"10.1016\/j.bcp.2025.117521_b0440","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0445","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-18-0972","article-title":"Inhibition of the replication stress response is a synthetic vulnerability in SCLC that acts synergistically in combination with cisplatin","volume":"18","author":"Nagel","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0450","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117521_b0455","doi-asserted-by":"crossref","unstructured":"J. J. Deppas, Brian F. Kiesel, J. Guo, R. A. Parise, D. A. Clump, D. Z. D\u2019Argenio, C. J. Bakkenist, J. H. Beumer, Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice, Cancer Chemother. Pharmacol. 94 (2) (2024) 271\u2013283, https:\/\/doi.org\/10.1007\/s00280-024-04675-3.","DOI":"10.1007\/s00280-024-04675-3"},{"key":"10.1016\/j.bcp.2025.117521_b0460","article-title":"Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer","volume":"45","author":"Telli","year":"2022","journal-title":"NPJ Breast Cancer 8"},{"key":"10.1016\/j.bcp.2025.117521_b0465","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2021.11.011","article-title":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","volume":"163","author":"Plummer","year":"2022","journal-title":"Lung Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2025.117521_b0470","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0475","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2025.117521_b0480","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of Ataxia telangiectasia mutated and rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0485","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117521_b0490","doi-asserted-by":"crossref","unstructured":"Y. Wallez, C. R. Dunlop, T. I. Johnson, S. B. Koh, C. Fornari, J. W. T. Yates, S. Bernaldo de Quir\u00f3s Fern\u00e1ndez, A. Lau, F. M. Richards, D. I. Jodrell, The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression, Mol. Cancer Ther. 17 (8) (2018) 1670\u20131682, https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0010.","DOI":"10.1158\/1535-7163.MCT-18-0010"},{"issue":"42","key":"10.1016\/j.bcp.2025.117521_b0495","doi-asserted-by":"crossref","first-page":"44289","DOI":"10.18632\/oncotarget.6247","article-title":"The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo","volume":"6","author":"Vendetti","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0500","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0505","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neo.2018.03.003","article-title":"Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer","volume":"20","author":"Jin","year":"2018","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.bcp.2025.117521_b0510","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2025.117521_b0515","doi-asserted-by":"crossref","unstructured":"A. Mostafa, K. Mulgrew, C. Lam, S. Hoffmann, D. Sutton, L. Carnevalli, F. J. CaleroNieto, G. N. Jones, A. J. Pierce, Z. Wilson, D. Campbell, L. Nyoni, C. P. Martins, T. Baker, G. S. de Almeida, Z. Ramlaoui, A. Bidar, B. Phillips, J. Boland, S. Iyer, J. C. Barrett, A. B. Loemb\u00e9, S. Y. Fuchs, U. Duvvuri, P. J. Lou, M. A. Nance1, C. A. G. Roca, E. Cadogan, S. E. Critichlow, S. Fawell, M. Cobbold, E. Dean, V. Valge-Archer, A. Lau, D. I. Gabrilovich, S. T. Barry, The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment, Nat. Commun. 15 (2024) 1700, https:\/\/doi.org\/10.1038\/s41467-024-45996-4.","DOI":"10.1038\/s41467-024-45996-4"},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0520","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker\u2010driven phase 2 umbrella trial: clinical efffcacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.bcp.2025.117521_b0525","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and Ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasma MATCH trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0530","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J. Immunother Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2025.117521_b0535","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1158\/1078-0432.CCR-21-0251","article-title":"Phase I study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"16 suppl","key":"10.1016\/j.bcp.2025.117521_b0540","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1200\/JCO.2024.42.16_suppl.8104","article-title":"A phase II, open-label, combination therapy of durvalumab and ceralasertib in relapsed and refractory small cell lung cancer (SUKSES-N4)","volume":"42","author":"Lee","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.bcp.2025.117521_b0545","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/JCO.2024.42.16_suppl.5510","article-title":"Combination ATR and PARP Inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)","volume":"42","author":"Simpkins","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117521_b0550","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","article-title":"ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)","volume":"31","author":"Banerjee","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2025.117521_b0555","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1535-7163.MCT-20-1026","article-title":"Novel and highly potent ATR inhibitor M-4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents","volume":"21","author":"Jo","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2025.117521_b0560","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117521_b0565","doi-asserted-by":"crossref","unstructured":"A. M. Wengner, G. Siemeister, U. L\u00fccking, J. Lefranc, L. Wortmann, P. Lienau, B. Bader, U. B\u00f6mer, D. Moosmayer, U. Ebersp\u00e4cher, S. Golfier, C. A. Schatz, S. J. Baumgart, B. Haendler, P. Lejeune, A. Schlicker, F. Nussbaum, M. Brands, K. Ziegelbauer, D. Mumberg, The novel ATR inhibitor BAY1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models, Mol. Cancer Ther. 19 (1) (2020) 26\u201338, https:\/\/doi. org\/10.1158\/1535-7163.mct-19-0019.","DOI":"10.1158\/1535-7163.MCT-19-0019"},{"key":"10.1016\/j.bcp.2025.117521_b0570","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117521_b0575","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral Ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.bcp.2025.117521_b0580","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1158\/2159-8290.CD-24-1500","article-title":"Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects","volume":"15","author":"Yap","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.117521_b0585","doi-asserted-by":"crossref","unstructured":"W. C. Black, A. Abdoli, X. An, A. Auger, P. Beaulieu, M. Bernatchez, C. Caron, A. Chefson, S. Crane, M. Diallo, S. Dorich, L. D. Fader, G. B. Ferraro, S. Fournier, Q. Gao, Y. Ginzburg, M. Hamel, Y. Han, P. Jones, S. Lanoix, C. M. Lacbay, M. Leclaire, M. Levy, Y. Mamane, A. Mulani, R. Papp, C. Pellerin, A. Picard, A. Skeldon, K. Skorey, R. Stocco, M. St.-Onge, J. Truchon, V. L. Truong, M. Zimmermann, M. Zinda, A. Roulston, Discovery of the potent and selective ATR inhibitor Camonsertib (RP-3500), J. Med. Chem. 67 (4) (2024) 2349\u20132368, https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01917.","DOI":"10.1021\/acs.jmedchem.3c01917"},{"key":"10.1016\/j.bcp.2025.117521_b0590","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bcp.2025.117521_b0595","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1158\/1535-7163.MCT-23-0402","article-title":"The novel ATR inhibitor tuvusertib (M1774) induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs","volume":"23","author":"Jo","year":"2024","journal-title":"Mol. Cancer Ther."},{"issue":"7 suppl","key":"10.1016\/j.bcp.2025.117521_b0600","doi-asserted-by":"crossref","first-page":"S747","DOI":"10.1016\/j.annonc.2022.07.586","article-title":"A phase I study of ATR inhibitor M1774 in patients with solid tumours (DDRiver Solid Tumours 301): Part A1 results","volume":"33","author":"Yap","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2025.117521_b0605","unstructured":"Z. Cai, Y. Tian, X. Wang, Substituted heteroaromatic bicyclic compounds as kinase inhibitors and their applications, 2020. CN112142744A, Dec 29."},{"issue":"2 suppl","key":"10.1016\/j.bcp.2025.117521_b0610","doi-asserted-by":"crossref","first-page":"S476","DOI":"10.1016\/j.annonc.2023.09.1867","article-title":"First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors","volume":"34","author":"Lin","year":"2023","journal-title":"Ann. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.bcp.2025.117521_b0615","article-title":"Preclinical evaluation of SC0245, a small molecule inhibitor of ATR kinase","volume":"38","author":"Wang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.bcp.2025.117521_b0620","article-title":"An open-label, single-arm, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of theATRinhibitorSC0245 in advanced solid malignancies","volume":"42","author":"Gong","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.bcp.2025.117521_b0625","doi-asserted-by":"crossref","first-page":"S8102","DOI":"10.1200\/JCO.2024.42.16_suppl.8102","article-title":"An open-label, multicenter, phase Ib\/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC)","volume":"42","author":"Yu","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"7 suppl","key":"10.1016\/j.bcp.2025.117521_b0630","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1158\/1538-7445.AM2023-6177","article-title":"Abstract 6177: ATRN-119 and ATRN-W1051: novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment","volume":"83","author":"Vacca","year":"2023","journal-title":"Cancer Res."},{"issue":"12 suppl","key":"10.1016\/j.bcp.2025.117521_b0635","doi-asserted-by":"crossref","first-page":"C147","DOI":"10.1158\/1535-7163.TARG-23-C147","article-title":"Abstract C147: The DNA replication checkpoint inhibitors, ATRN-1051(WEE1i) and ATRN-119 (ATRi), are potentially well tolerated and effective cancer treatments","volume":"22","author":"Vacca","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.bcp.2025.117521_b0640","doi-asserted-by":"crossref","first-page":"21890","DOI":"10.1021\/acs.jmedchem.4c01595","article-title":"Discovery of ART0380, a potent and selective ATR kinase inhibitor undergoing phase 2 clinical studies for the treatment of advanced or metastatic solid cancers","volume":"67","author":"Carroll","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2025.117521_b0645","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1021\/acs.jmedchem.4c02380","article-title":"Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2025.117521_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116159","article-title":"Discovery of the first Ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment","volume":"267","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0655","first-page":"485","article-title":"Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice","volume":"15","author":"Kong","year":"2023","journal-title":"Chin. Herb. Med."},{"issue":"3","key":"10.1016\/j.bcp.2025.117521_b0660","first-page":"449","article-title":"Tea and Citrus maxima complex induces apoptosis of human liver cancer cells via PI3K\/AKT\/mTOR pathway in vitro","volume":"14","author":"Wen","year":"2022","journal-title":"Chin. Herb. Med."},{"issue":"1","key":"10.1016\/j.bcp.2025.117521_b0665","first-page":"94","article-title":"Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K\/AKT\/mTOR and EMT pathways","volume":"16","author":"Chen","year":"2024","journal-title":"Chin. Herb. Med."},{"issue":"4","key":"10.1016\/j.bcp.2025.117521_b0670","first-page":"509","article-title":"Traditional Chinese medicines for non-small cell lung cancer: therapies and mechanisms","volume":"15","author":"Kong","year":"2023","journal-title":"Chin. Herb. Med."},{"issue":"8","key":"10.1016\/j.bcp.2025.117521_b0675","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.3390\/molecules27082491","article-title":"Recent advances in synergistic antitumor effects exploited from the inhibition of Ataxia telangiectasia and RAD3-related protein kinase (ATR)","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225007865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:24:41Z","timestamp":1781065481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225007865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":135,"alternative-id":["S0006295225007865"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117521","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in developing ATR inhibitors as anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117521"}}